CSPC PHARMA(01093.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 6.09 billion, YoY increase of 139.19%

NewTimeSpace News: August 20, 2026, CSPC PHARMA(01093.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 18.59 billion, increased by 40.09% YoY; Net Profit stood at CNY 6.46 billion, YoY increase of 150.97%; Profit Attributable to Shareholders stood at CNY 6.09 billion, YoY increase of 139.19%; Basic Earnings Per Share (EPS) stood at CNY 0.53.

In terms of profitability, CSPC PHARMA Gross Profit changed from CNY 8.71 billion in the same period last year to CNY 14.16 billion in the current period, increased by CNY 5.45 billion; gross profit margin changed from 65.62% in the same period last year to 76.15% in the current period, increased by 10.53 percentage points; net profit changed from CNY 2.57 billion in the same period last year to CNY 6.46 billion in the current period, increased by CNY 3.89 billion; net profit margin changed from 19.39% in the same period last year to 34.74% in the current period, increased by 15.35 percentage points. 

In terms of earnings quality, CSPC PHARMA Operating Profit changed from CNY 3.15 billion in the same period last year to CNY 7.55 billion in the current period, increased by CNY 4.39 billion; Operating Profit Margin changed from 23.75% in the same period last year to 40.58% in the current period, increased by 16.84 percentage points. 

In terms of R&D investment focus, CSPC PHARMA R&D Expenses changed from CNY 2.68 billion in the same period last year to CNY 3.03 billion in the current period, increased by CNY 346.83 million; R&D to Total Revenue Ratio changed from 20.21% in the same period last year to 16.29% in the current period, decreased by 3.92 percentage points. 

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.